Royalty Pharma Financial Ratios
NASDAQ: RPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Royalty Pharma ratio analysis
Royalty Pharma earned a net margin of 32.4% in FY 2025, down from 37.9% a year earlier. Return on equity reached 7.9%, meaning Royalty Pharma generated 0.08 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.92 versus 0.74 the year before, and the current ratio was 2.40.
At the end of FY 2025, RPRX traded at 21.8 times earnings; across the 6 fiscal years shown, its year-end P/E ranged from 11.1 to 395.2, with a median of 24.3. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Royalty Pharma financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 21.83 | 13.53 | 11.10 | 395.20 | 26.74 | 37.92 | — | — |
| Price / sales | 7.02 | 5.12 | 5.34 | 7.74 | 7.22 | 8.85 | — | — |
| Price / book | 1.72 | 1.12 | 1.25 | 1.82 | 1.61 | 1.90 | — | — |
| Operating margin | 65.6% | 57.1% | 63.4% | 13.7% | 62.5% | 75.2% | 144.6% | 76.0% |
| Net margin | 32.4% | 37.9% | 48.2% | 1.9% | 27.1% | 45.9% | 129.4% | 76.8% |
| Free cash flow margin | 104.7% | 122.3% | 126.9% | 95.8% | 88.1% | 95.9% | 91.9% | 90.2% |
| Return on equity (ROE) | 7.9% | 8.3% | 11.3% | 0.4% | 6.0% | 9.9% | 38.2% | 30.3% |
| Return on assets (ROA) | 3.9% | 4.7% | 6.9% | 0.3% | 3.5% | 6.1% | 18.9% | — |
| Debt / equity | 0.92 | 0.74 | 0.61 | 0.75 | 0.69 | 0.59 | 1.02 | — |
| Current ratio | 2.40 | 1.44 | 7.90 | 2.19 | 16.81 | 8.76 | 2.50 | — |
| Revenue growth | 5.1% | -3.9% | 5.2% | -2.3% | 7.9% | 17.0% | 1.1% | — |
| EPS growth | -6.8% | -24.5% | 2,430.0% | -93.3% | 12.9% | — | — | — |